Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease.

Cast A, Kumbaji M, D'Souza A, Rodriguez K, Gupta A, Karns R, Timchenko L, Timchenko N.

Hepatol Commun. 2019 Jul 17;3(8):1036-1049. doi: 10.1002/hep4.1381. eCollection 2019 Aug.

2.

Toxin-Antitoxin Systems And Their Role In Maintaining The Pathogenic Potential Of Causative Agents Of Sapronoses.

Andryukov BG, Somova LM, Timchenko NF, Bynina MP, Lyapun IN.

Infect Disord Drug Targets. 2019 Jul 15. doi: 10.2174/1871526519666190715150444. [Epub ahead of print]

PMID:
31322076
3.

NR2E3 is a key component in p53 activation by regulating a long noncoding RNA DINO in acute liver injuries.

Khanal T, Leung YK, Jiang W, Timchenko N, Ho SM, Kim K.

FASEB J. 2019 Jul;33(7):8335-8348. doi: 10.1096/fj.201801881RR. Epub 2019 Apr 16.

PMID:
30991008
4.

PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma.

Valanejad L, Cast A, Wright M, Bissig KD, Karns R, Weirauch MT, Timchenko N.

Commun Biol. 2018 Jun 11;1:67. doi: 10.1038/s42003-018-0077-8. eCollection 2018.

5.

Gankyrin Promotes Tumor-Suppressor Protein Degradation to Drive Hepatocyte Proliferation.

D'Souza AM, Jiang Y, Cast A, Valanejad L, Wright M, Lewis K, Kumbaji M, Shah S, Smithrud D, Karns R, Shin S, Timchenko N.

Cell Mol Gastroenterol Hepatol. 2018 May 24;6(3):239-255. doi: 10.1016/j.jcmgh.2018.05.007. eCollection 2018.

6.

Correction of aging phenotype in the liver.

Rodriguez K, Cast A, Timchenko NA.

Aging (Albany NY). 2018 Aug 10;10(8):1795-1796. doi: 10.18632/aging.101523. No abstract available.

7.

Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBPα-p300 Axis.

Nguyen P, Valanejad L, Cast A, Wright M, Garcia JM, El-Serag HB, Karns R, Timchenko NA.

Cell Rep. 2018 Aug 7;24(6):1597-1609. doi: 10.1016/j.celrep.2018.07.014.

8.

Reduction of Cellular Nucleic Acid Binding Protein Encoded by a Myotonic Dystrophy Type 2 Gene Causes Muscle Atrophy.

Wei C, Stock L, Schneider-Gold C, Sommer C, Timchenko NA, Timchenko L.

Mol Cell Biol. 2018 Jun 28;38(14). pii: e00649-17. doi: 10.1128/MCB.00649-17. Print 2018 Jul 15.

9.

Correction of GSK3β at young age prevents muscle pathology in mice with myotonic dystrophy type 1.

Wei C, Stock L, Valanejad L, Zalewski ZA, Karns R, Puymirat J, Nelson D, Witte D, Woodgett J, Timchenko NA, Timchenko L.

FASEB J. 2018 Apr;32(4):2073-2085. doi: 10.1096/fj.201700700R. Epub 2018 Jan 5.

10.

C/EBPα-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer.

Cast A, Valanejad L, Wright M, Nguyen P, Gupta A, Zhu L, Shin S, Timchenko N.

Hepatology. 2018 May;67(5):1857-1871. doi: 10.1002/hep.29677. Epub 2018 Mar 25.

PMID:
29159818
11.

Intravenous miR-144 inhibits tumor growth in diethylnitrosamine-induced hepatocellular carcinoma in mice.

He Q, Wang F, Honda T, Lindquist DM, Dillman JR, Timchenko NA, Redington AN.

Tumour Biol. 2017 Oct;39(10):1010428317737729. doi: 10.1177/1010428317737729.

PMID:
29072132
12.

Ghrelin deletion protects against age-associated hepatic steatosis by downregulating the C/EBPα-p300/DGAT1 pathway.

Guillory B, Jawanmardi N, Iakova P, Anderson B, Zang P, Timchenko NA, Garcia JM.

Aging Cell. 2018 Feb;17(1). doi: 10.1111/acel.12688. Epub 2017 Oct 12.

13.

Mitochondrial and anabolic pathways in hepatocellular carcinoma.

Timchenko NA.

Hepatology. 2018 Mar;67(3):823-825. doi: 10.1002/hep.29559. Epub 2018 Jan 30. No abstract available.

PMID:
28960377
14.

RNA Binding Protein CUGBP1 Inhibits Liver Cancer in a Phosphorylation-Dependent Manner.

Lewis K, Valanejad L, Cast A, Wright M, Wei C, Iakova P, Stock L, Karns R, Timchenko L, Timchenko N.

Mol Cell Biol. 2017 Jul 28;37(16). pii: e00128-17. doi: 10.1128/MCB.00128-17. Print 2017 Aug 15.

15.

FXR-Gankyrin axis is involved in development of pediatric liver cancer.

Valanejad L, Lewis K, Wright M, Jiang Y, D'Souza A, Karns R, Sheridan R, Gupta A, Bove K, Witte D, Geller J, Tiao G, Nelson DL, Timchenko L, Timchenko N.

Carcinogenesis. 2017 Jul 1;38(7):738-747. doi: 10.1093/carcin/bgx050.

16.

[BIOLOGICAL ACTIVITY OF YERSINIA PSEUDOTUBERCULOSIS TOXINS].

Terentieva NA, Timchenko NF, Golotin VA, Rasskazov VA.

Zh Mikrobiol Epidemiol Immunobiol. 2016 Nov;(6):10-19. Russian.

PMID:
30695384
17.

Activation of CDK4 Triggers Development of Non-alcoholic Fatty Liver Disease.

Jin J, Valanejad L, Nguyen TP, Lewis K, Wright M, Cast A, Stock L, Timchenko L, Timchenko NA.

Cell Rep. 2016 Jul 19;16(3):744-56. doi: 10.1016/j.celrep.2016.06.019. Epub 2016 Jun 30.

18.

Generation of pediatric liver cancer patient-derived xenograft platforms for pediatric liver cancer: A critical stage in the development of anticancer treatments.

Tiao G, Geller J, Timchenko NA.

Hepatology. 2016 Oct;64(4):1017-9. doi: 10.1002/hep.28711. Epub 2016 Aug 2. No abstract available.

PMID:
27359258
19.

Akt-FoxO1 axis controls liver regeneration.

Valanejad L, Timchenko N.

Hepatology. 2016 May;63(5):1424-6. doi: 10.1002/hep.28440. Epub 2016 Mar 9. No abstract available.

PMID:
27100144
20.

Far East Scarlet-Like Fever Caused by a Few Related Genotypes of Yersinia pseudotuberculosis, Russia.

Timchenko NF, Adgamov RR, Popov AF, Psareva EK, Sobyanin KA, Gintsburg AL, Ermolaeva SA.

Emerg Infect Dis. 2016 Mar;22(3):503-6. doi: 10.3201/eid2203.150552.

21.

SRC-2 orchestrates polygenic inputs for fine-tuning glucose homeostasis.

Fleet T, Zhang B, Lin F, Zhu B, Dasgupta S, Stashi E, Tackett B, Thevananther S, Rajapakshe KI, Gonzales N, Dean A, Mao J, Timchenko N, Malovannaya A, Qin J, Coarfa C, DeMayo F, Dacso CC, Foulds CE, O'Malley BW, York B.

Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):E6068-77. doi: 10.1073/pnas.1519073112. Epub 2015 Oct 20.

22.

The Glutamine-Alanine Repeat Domain of TCERG1 is Required for the Inhibition of the Growth Arrest Activity of C/EBPα.

Miller NJ, Schick K, Timchenko N, Harrison E, Roesler WJ.

J Cell Biochem. 2016 Mar;117(3):612-20. doi: 10.1002/jcb.25309.

PMID:
26264132
23.

[CHARACTERISTICS OF FORMATION, INHIBITION AND DESTRUCTION OF YERSINIA PSEUDOTUBERCULOSIS BIOFILMS FORMING ON ABIOTIC SURFACES].

Terentieval NA, Timchenko NF, Balabanova LA, Rasskazov VA.

Zh Mikrobiol Epidemiol Immunobiol. 2015 May-Jun;(3):72-8. Russian.

PMID:
26259274
24.

p300 Regulates Liver Functions by Controlling p53 and C/EBP Family Proteins through Multiple Signaling Pathways.

Breaux M, Lewis K, Valanejad L, Iakova P, Chen F, Mo Q, Medrano E, Timchenko L, Timchenko N.

Mol Cell Biol. 2015 Sep 1;35(17):3005-16. doi: 10.1128/MCB.00421-15. Epub 2015 Jun 22.

25.

Reduction of toxic RNAs in myotonic dystrophies type 1 and type 2 by the RNA helicase p68/DDX5.

Jones K, Wei C, Schoser B, Meola G, Timchenko N, Timchenko L.

Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8041-5. doi: 10.1073/pnas.1422273112. Epub 2015 Jun 15.

26.

Cell-type specific functions of epidermal growth factor receptor are involved in development of hepatocellular carcinoma.

Timchenko NA.

Hepatology. 2015 Jul;62(1):314-6. doi: 10.1002/hep.27863. Epub 2015 May 20. No abstract available.

27.

Effect of thermolabile toxin from Yersinia pseudotuberculosis on functions of innate immunity cells.

Plekhova NG, Drobot EI, Timchenko NF, Somova LM, Persiyanova EN.

Bull Exp Biol Med. 2014 Aug;157(4):483-7. doi: 10.1007/s10517-014-2597-7. Epub 2014 Aug 12.

PMID:
25110089
28.

Cooperation of C/EBP family proteins and chromatin remodeling proteins is essential for termination of liver regeneration.

Jin J, Hong IH, Lewis K, Iakova P, Breaux M, Jiang Y, Sullivan E, Jawanmardi N, Timchenko L, Timchenko NA.

Hepatology. 2015 Jan;61(1):315-25. doi: 10.1002/hep.27295. Epub 2014 Nov 20.

29.

Age-associated change of C/EBP family proteins causes severe liver injury and acceleration of liver proliferation after CCl4 treatments.

Hong IH, Lewis K, Iakova P, Jin J, Sullivan E, Jawanmardi N, Timchenko L, Timchenko N.

J Biol Chem. 2014 Jan 10;289(2):1106-18. doi: 10.1074/jbc.M113.526780. Epub 2013 Nov 22.

30.

Farnesoid X receptor directly regulates xenobiotic detoxification genes in the long-lived Little mice.

Jiang Y, Jin J, Iakova P, Hernandez JC, Jawanmardi N, Sullivan E, Guo GL, Timchenko NA, Darlington GJ.

Mech Ageing Dev. 2013 Sep;134(9):407-15. doi: 10.1016/j.mad.2013.08.003. Epub 2013 Sep 2.

31.

Nonenzymatic test system for noninstrumental determination of antibodies to species-specific fibers of Yersinia pseudotuberculosis on the basis of nanosized carbon particles.

Rayev MB, Timchenko NF, Bochkova MS, Nedashkovskaya EP, Andrukov BG.

Dokl Biochem Biophys. 2013 Jul-Aug;451:221-4. doi: 10.1134/S1607672913040169. Epub 2013 Aug 23. No abstract available.

PMID:
23975407
32.

Transcriptional and translational regulation of C/EBPβ-HDAC1 protein complexes controls different levels of p53, SIRT1, and PGC1α proteins at the early and late stages of liver cancer.

Jin J, Iakova P, Jiang Y, Lewis K, Sullivan E, Jawanmardi N, Donehower L, Timchenko L, Timchenko NA.

J Biol Chem. 2013 May 17;288(20):14451-62. doi: 10.1074/jbc.M113.460840. Epub 2013 Apr 5.

33.

Increased expression of enzymes of triglyceride synthesis is essential for the development of hepatic steatosis.

Jin J, Iakova P, Breaux M, Sullivan E, Jawanmardi N, Chen D, Jiang Y, Medrano EM, Timchenko NA.

Cell Rep. 2013 Mar 28;3(3):831-43. doi: 10.1016/j.celrep.2013.02.009. Epub 2013 Mar 14.

34.

GSK3β is a new therapeutic target for myotonic dystrophy type 1.

Wei C, Jones K, Timchenko NA, Timchenko L.

Rare Dis. 2013 Sep 26;1:e26555. doi: 10.4161/rdis.26555. eCollection 2013.

35.

[Efficiency of a new synbiotic drink in treatment of chronic diseases of gastrointestinal tract and concomitant dysbacteriosis].

Kuznetsova TA, Zaporozhets TS, Besedova NN, Timchenko NF, Kryzhanovskiĭ SP, Golovacheva VD, Zviagintseva TN, Shevchenko NM.

Antibiot Khimioter. 2013;58(9-10):21-6. Russian.

PMID:
24738239
36.

Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.

Jiang Y, Iakova P, Jin J, Sullivan E, Sharin V, Hong IH, Anakk S, Mayor A, Darlington G, Finegold M, Moore D, Timchenko NA.

Hepatology. 2013 Mar;57(3):1098-106. doi: 10.1002/hep.26146. Epub 2013 Feb 15.

37.

GSK3β mediates muscle pathology in myotonic dystrophy.

Jones K, Wei C, Iakova P, Bugiardini E, Schneider-Gold C, Meola G, Woodgett J, Killian J, Timchenko NA, Timchenko LT.

J Clin Invest. 2012 Dec;122(12):4461-72. doi: 10.1172/JCI64081. Epub 2012 Nov 19.

38.

[Clinical signs of endothelial disorders in patients with severe sepsis].

Plotkin LL, Bespalov AM, Smirnov DM, Timchenko NN, Shapovalova IuS, Konradi AB.

Anesteziol Reanimatol. 2012 Mar-Apr;(2):48-51. Russian.

PMID:
22834288
39.

Variability in the functional domains of the rho-modifying toxins of Yersinia pseudotuberculosis.

Timchenko N, Adgamov R, Ermolaeva S.

Adv Exp Med Biol. 2012;954:261-6. doi: 10.1007/978-1-4614-3561-7_33. No abstract available.

PMID:
22782772
40.

The role of CUGBP1 in age-dependent changes of liver functions.

Jones K, Timchenko L, Timchenko NA.

Ageing Res Rev. 2012 Sep;11(4):442-9. doi: 10.1016/j.arr.2012.02.007. Epub 2012 Mar 14. Review.

41.

RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2.

Jones K, Jin B, Iakova P, Huichalaf C, Sarkar P, Schneider-Gold C, Schoser B, Meola G, Shyu AB, Timchenko N, Timchenko L.

Am J Pathol. 2011 Nov;179(5):2475-89. doi: 10.1016/j.ajpath.2011.07.013. Epub 2011 Sep 1.

42.

The reduction of SIRT1 in livers of old mice leads to impaired body homeostasis and to inhibition of liver proliferation.

Jin J, Iakova P, Jiang Y, Medrano EE, Timchenko NA.

Hepatology. 2011 Sep 2;54(3):989-98. doi: 10.1002/hep.24471. Epub 2011 Jul 27.

43.

[Immunogenic and protective properties of nanosized constructs based on tubular immunostimulating complexes and pore forming protein of Yersinia pseudotuberculosis].

Tsybul'skiĭ AV, Popov AM, Sanina NM, Mazeĭka AN, Portniagina OIu, Novikova OD, Timchenko NF, Kostetskiĭ ÉIa.

Zh Mikrobiol Epidemiol Immunobiol. 2011 Mar-Apr;(2):43-7. Russian.

PMID:
21598614
44.

Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML.

Haefliger S, Klebig C, Schaubitzer K, Schardt J, Timchenko N, Mueller BU, Pabst T.

Blood. 2011 Jun 2;117(22):5931-40. doi: 10.1182/blood-2010-08-304485. Epub 2011 Apr 6.

45.

Intracellular signaling and hepatocellular carcinoma.

Iakova P, Timchenko L, Timchenko NA.

Semin Cancer Biol. 2011 Feb;21(1):28-34. doi: 10.1016/j.semcancer.2010.09.001. Epub 2010 Sep 17. Review.

46.

Epigenetic changes play critical role in age-associated dysfunctions of the liver.

Jin J, Wang GL, Iakova P, Shi X, Haefliger S, Finegold M, Timchenko NA.

Aging Cell. 2010 Oct;9(5):895-910. doi: 10.1111/j.1474-9726.2010.00617.x.

47.

Elimination of C/EBPalpha through the ubiquitin-proteasome system promotes the development of liver cancer in mice.

Wang GL, Shi X, Haefliger S, Jin J, Major A, Iakova P, Finegold M, Timchenko NA.

J Clin Invest. 2010 Jul;120(7):2549-62. doi: 10.1172/JCI41933.

48.

Calmodulin controls liver proliferation via interactions with C/EBPbeta-LAP and C/EBPbeta-LIP.

Orellana D, Liu X, Wang GL, Jin J, Iakova P, Timchenko NA.

J Biol Chem. 2010 Jul 23;285(30):23444-56. doi: 10.1074/jbc.M110.129825. Epub 2010 May 24.

49.

Expansion of CUG RNA repeats causes stress and inhibition of translation in myotonic dystrophy 1 (DM1) cells.

Huichalaf C, Sakai K, Jin B, Jones K, Wang GL, Schoser B, Schneider-Gold C, Sarkar P, Pereira-Smith OM, Timchenko N, Timchenko L.

FASEB J. 2010 Oct;24(10):3706-19. doi: 10.1096/fj.09-151159. Epub 2010 May 17.

50.

SKI promotes Smad3 linker phosphorylations associated with the tumor-promoting trait of TGFbeta.

Lin Q, Chen D, Timchenko NA, Medrano EE.

Cell Cycle. 2010 May;9(9):1684-9. Epub 2010 May 21.

Supplemental Content

Loading ...
Support Center